Literature DB >> 24447606

Detection of the index tumour and tumour volume in prostate cancer using T2-weighted and diffusion-weighted magnetic resonance imaging (MRI) alone.

Erik Rud1, Dagmar Klotz2, Kristin Rennesund3, Eduard Baco3, Viktor Berge3, Diep Lien4, Aud Svindland5, Eskild Lundeby3, Rolf E Berg3, Lars M Eri3, Heidi B Eggesbø6.   

Abstract

OBJECTIVE: To examine the performance of T2-weighted (T2W) and diffusion-weighted (DW) magnetic resonance imaging (MRI) for detecting the index tumour in patients with prostate cancer and to examine the agreement between MRI and histology when assessing tumour volume (TV) and overall tumour burden. PATIENTS AND METHODS: The study included 199 consecutive patients with biopsy confirmed prostate cancer randomised to MRI before radical prostatectomy from December 2009 to July 2012. MRI-detected tumours (MRTs) were ranked from 1 to 3 according to decreasing volume and were compared with histologically detected tumours (HTs) ranked from 1 to 3, with HT 1 = index tumour. Whole-mount section histology was used as a reference standard. The TVs of true-positive MRTs (MRTVs 1-3) were compared with the TVs found by histology (HTVs 1-3). All tumours were registered on a 30-sector map and by classifying each sector as positive/negative, the rate of true-positive and -negative sectors was calculated.
RESULTS: The detection rate for the HT 1 (index tumour) was 92%; HT 2, 45%; and HT 3, 37%. The MRTV 1-3 vs the HTV 1-3 were 2.8 mL vs 4.0 mL (index tumour, P < 0.001), 1.0 mL vs 0.9 mL (tumour 2, P = 0.413), and 0.6 mL vs 0.5 mL (tumour 3, P = 0.492). The rate of true-positive and -negative sectors was 50% and 88%, κ = 0.39.
CONCLUSION: A combination of T2W and DW MRI detects the index tumour in 92% of cases, although MRI underestimates both TV and tumour burden compared with histology.
© 2014 The Authors. BJU International © 2014 BJU International.

Entities:  

Keywords:  MRI; diffusion-weighted MRI; index tumour; prostate cancer; tumour volume

Mesh:

Year:  2014        PMID: 24447606     DOI: 10.1111/bju.12637

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  35 in total

1.  [Multiparametric MRI and MRI-TRUS fusion biopsy in patients with prior negative prostate biopsy].

Authors:  C Kesch; J P Radtke; F Distler; S Boxler; T Klein; C Hüttenbrink; K Hees; W Roth; M Roethke; H P Schlemmer; M Hohenfellner; B A Hadaschik
Journal:  Urologe A       Date:  2016-08       Impact factor: 0.639

2.  Poor standard mp-MRI and routine biopsy fail to precisely predict intraprostatic tumor localization.

Authors:  Andrea Billing; Alexander Buchner; Christian Stief; Alexander Roosen
Journal:  World J Urol       Date:  2016-02-24       Impact factor: 4.226

3.  Intraprostatic ethanol diffusion: comparison of two injection methods using ex vivo human prostates.

Authors:  B J King; T K Mann-Gow; M Kida; M K Plante; S D Perrapato; P Zvara
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-05-26       Impact factor: 5.554

Review 4.  [Prostate gland - what would urologists like to know from radiologists?]

Authors:  U B Liehr; D Baumunk; S Blaschke; F Fischbach; B Friebe; F König; A Lemke; P Mittelstädt; M Pech; M Porsch; J Ricke; D Schindele; S Siedentopf; J J Wendler; M Schostak
Journal:  Radiologe       Date:  2017-08       Impact factor: 0.635

5.  Comparison of free-hand transperineal mpMRI/TRUS fusion-guided biopsy with transperineal 12-core systematic biopsy for the diagnosis of prostate cancer: a single-center prospective study in China.

Authors:  Qing Zhang; Wei Wang; Bing Zhang; Jong Shi; Yao Fu; Danyan Li; Suhan Guo; Shengjie Zhang; Haifeng Huang; Xuping Jiang; Weimin Zhou; Hongqian Guo
Journal:  Int Urol Nephrol       Date:  2016-12-22       Impact factor: 2.370

Review 6.  Functional magnetic resonance imaging and molecular pathology at the crossroad of the management of early prostate cancer.

Authors:  Raphaele Renard-Penna; Geraldine Cancel-Tassin; Eva Comperat; Morgan Roupret; Pierre Mozer; Olivier Cussenot
Journal:  World J Urol       Date:  2015-05-06       Impact factor: 4.226

7.  Improved detection of anterior fibromuscular stroma and transition zone prostate cancer using biparametric and multiparametric MRI with MRI-targeted biopsy and MRI-US fusion guidance.

Authors:  J P Radtke; S Boxler; T H Kuru; M B Wolf; C D Alt; I V Popeneciu; S Steinemann; C Huettenbrink; C Bergstraesser-Gasch; T Klein; C Kesch; M Roethke; N Becker; W Roth; H-P Schlemmer; M Hohenfellner; B A Hadaschik
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-06-16       Impact factor: 5.554

8.  A novel biopsy-related parameter derived from location and relationship of positive cores on standard 12-core trans-rectal ultrasound-guided prostate biopsy: a useful parameter for predicting tumor volume compared to number of positive cores.

Authors:  Sangjun Yoo; Hwancheol Son; Sohee Oh; Juhyun Park; Sung Yong Cho; Min Chul Cho; Hyeon Jeong
Journal:  J Cancer Res Clin Oncol       Date:  2017-09-22       Impact factor: 4.553

9.  Tumour volume of resectable oesophageal squamous cell carcinoma measured with MRI correlates well with T category and lymphatic metastasis.

Authors:  Lan Wu; Jing Ou; Tian-Wu Chen; Rui Li; Xiao-Ming Zhang; Yan-Li Chen; Yu Jiang; Jian-Qiong Yang; Jin-Ming Cao
Journal:  Eur Radiol       Date:  2018-05-14       Impact factor: 5.315

Review 10.  Current status and future prospective of focal therapy for localized prostate cancer: development of multiparametric MRI, MRI-TRUS fusion image-guided biopsy, and treatment modalities.

Authors:  Sunao Shoji; Shinichiro Hiraiwa; Izumi Hanada; Hakushi Kim; Masahiro Nitta; Masanori Hasegawa; Yoshiaki Kawamura; Kazunobu Hashida; Takuma Tajiri; Akira Miyajima
Journal:  Int J Clin Oncol       Date:  2020-02-10       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.